A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

ClinicalTrials.gov ID: NCT04139304

Public ClinicalTrials.gov record NCT04139304. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a monoclonal antibody that specifically targets CD38 expressing cells, and may help the body's immune system attack the cancer and interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab may enhance the effectiveness of a standard chemotherapy (DA-EPOCH) in patients with plasmablastic lymphoma.

Study identification

NCT ID: NCT04139304
Recruitment status: Recruiting
Study type: Interventional
Phase: Early Phase 1
Lead sponsor: AIDS Malignancy Consortium; Network
Enrollment: 15 participants

Conditions and interventions

Conditions

Interventions

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 23, 2021
Primary completion: Jun 30, 2029
Completion: Jun 30, 2030
Last update posted: May 31, 2026

2021 – 2030

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of Miami Miller School of Medicine	Miami	Florida	33136	Recruiting
University of Illinois at Chicago	Chicago	Illinois	60612	Recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore	Maryland	21231	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10021	Recruiting
University of North Carolina - Chapel Hill	Chapel Hill	North Carolina	27514	Recruiting
The Ohio State University	Columbus	Ohio	43210	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04139304, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 31, 2026 · Synced Sep 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04139304 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →